COVID-19 IN CHILDREN IN NIGER, 2020

May 31, 2023 updated by: IDE AMADOU Habibatou, Centre de Recherche Médicale et Sanitaire

Factors Associated With COVID-19 in Children Aged 0-15 Years in Niger, 2020

On January 30, 2020, the WHO declared COVID-19 a global health emergency. Children were affected with less severe forms. Niger had implemented measures in a context where children are a source of contamination. The objective was to determine the factors associated with COVID-19 in children in Niger from February to August 2020 through an analysis of the national database.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

We conducted an analytical cross-sectional study including all COVID-19 suspects in the database. We used Excel and Epi Info 7.2.4. software for data extraction and analysis. Frequencies and proportions were calculated, we estimated in a logistic regression the OR of association with their 95% confidence interval, the factors associated with COVID-19 at the threshold of p<0.05.

Results: Of 572 notified suspected COVID-19 cases in children aged 0-15 years, 11.36% were positive. The median age of infected children was 10 years [IQR: 5- 13 years]. The sex ratio of males to females was 2.1. Children aged 11-15 years were 49.2%, 61.5% resided in Niamey, 4.6% had comorbidities. The notion of travel was 12.3% and 40% had a notion of contact, 24.4% had a fever, 23.2% had a cough, 18% were hospitalized and the case fatality was 1.5%. In etiological analysis, the factors associated with COVID-19 were sex ORa= 0.51 [0.28-0.93] p=0.028, the presence of symptoms ORa= 2.29 [1.23-4.25] p=0.008 and the notion of contact ORa= 0.32 [0.13-0.77] p=0.011.

exposed children were sensitive to COVID-19, all age groups were affected with a male predominance. We recommend barrier measures adapted to young people, early detection and management of infected children.

Study Type

Observational

Enrollment (Actual)

572

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Niger
      • Niamey, Niger, BP: 10887, Niamey, Niger
        • IDE AMADOU Habibatou

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This was an analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger. The study period spanned six (6) months from February 25 to August 28, 2020. Children aged 0-15 years suspected of having COVID-19 whose data were in the DSRE database were included. We used the data extraction form that served as a secondary database containing only our variables of interest.

Description

Inclusion Criteria:

  • Children aged 0-15 years suspected of having COVID-19 whose data were in the DSRE database were included

Exclusion Criteria:

  • Children whose data is not complete

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
data base analysis
Time Frame: May 2021
The first step concerned the descriptive part where the frequencies, proportions, means and extreme values of the variables were calculated. Some of these variables were presented in the form of tables and graphs.
May 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre de Recherche Médicale et Sanitaire

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 25, 2020

Primary Completion (Actual)

August 28, 2020

Study Completion (Actual)

January 15, 2021

Study Registration Dates

First Submitted

May 31, 2023

First Submitted That Met QC Criteria

May 31, 2023

First Posted (Estimated)

June 2, 2023

Study Record Updates

Last Update Posted (Estimated)

June 2, 2023

Last Update Submitted That Met QC Criteria

May 31, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CERMES

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

What is IPD ?

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe